No Data
No Data
No Data
No Data
No Data
Reunion Neuroscience On The Brink Of Going Private With Final Court Approval
Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ:REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution a
BenzingaJul 17, 2023 17:04 ET
Reunion Neuroscience's Q4 And Full Year 2023 Financial Results, To Close Take-Private Deal In Q3
Clinical-stage psychedelics firm Reunion Neuroscience Inc. (NASDAQ:REUN) reported fiscal results for the fourth quarter and year ended March 31 plus corporate updates. Here's a breakdown of the report
BenzingaJun 29, 2023 13:22 ET
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB:PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic keta
BenzingaJun 27, 2023 18:05 ET
Can Field Trip Health & Wellness Re-Emerge From Creditor Protection? What The CCAA Data Shows
Potentially, a significant business casualty has befallen the psychedelic sector. Early industry leader, Field Trip Health & Wellness (OTC:FTHWF), has announced that it has obtained an Order for credi
BenzingaMar 27, 2023 13:04 ET
Express News | Field Trip Health & Wellness Ltd. Brief: Says Has Obtained CCAA Protection
Moomoo 24/7Mar 22, 2023 14:16 ET
In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?
Closely following the announcement of what's to become of the new regulations for telehealth, including ketamine therapy, several of in-clinic treatment centers have announced they are closing their o
BenzingaMar 15, 2023 13:43 ET
No Data
No Data